Celcuity Inc. (CELC) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Minneapolis, MN, United States. Der aktuelle CEO ist Brian F. Sullivan.
CELC hat IPO-Datum 2017-09-20, 87 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $5.84B.
Celcuity Inc. is a clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, focused on developing molecularly targeted cancer therapies for patients in the United States. The company's proprietary CELsignia diagnostic platform analyzes living tumor cells to identify the specific cellular abnormalities driving a patient's cancer and determines the most appropriate targeted treatment approach. Its lead drug candidate, Gedatolisib, selectively targets PI3K and mTOR pathways and is being evaluated for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer under a license agreement with Pfizer. Celcuity is also advancing the CELsignia MP test, a laboratory-developed diagnostic that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor samples to guide therapeutic selection.
